Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

To improve clinical outcomes and shorten the vein-to-vein time of chimeric antigen receptor T (CAR-T) cells, we developed the FasT CAR-T (F-CAR-T) next-day manufacturing platform. We report the preclinical and first-in-human clinical studies evaluating the safety, feasibility, and preliminary effica...

Full description

Bibliographic Details
Main Authors: Cao, W. (Author), He, J. (Author), Li, J. (Author), Lu, P. (Author), Qiu, L. (Author), Sersch, M. (Author), Shen, L. (Author), Sun, Z. (Author), Wang, Z. (Author), Wu, Q. (Author), Yang, J. (Author), Ye, X. (Author), Yin, W. (Author), Zhang, X. (Author), Zhang, Y. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items